Source:http://linkedlifedata.com/resource/pubmed/id/11561767
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2001-9-19
|
pubmed:abstractText |
This was a non-randomised single institution retrospective study. Forty-six banked frozen tumour specimens were obtained from a group of patients who had undergone 3 weeks of neoadjuvant treatment with tamoxifen between biopsy and surgery. Fifty-one comparison specimens were randomly selected from a group of concomitantly treated primary breast cancer patients who did not receive neoadjuvant tamoxifen. Specimen selection was not based on prognostic factors: hormone receptor status, patient age, or menopausal status. MUC1 expression and cell cycle distribution were assessed by flow cytometry. S-phase fraction of MUC1 positive and MUC1 negative cells were compared. A lower percentage of cells expressed MUC1 following 3-week tamoxifen treatment 18.2% versus 28.5% (p = 0.03, Mann-Whitney) and lower levels of MUC1 expression were seen following tamoxifen treatment 31,519 molecules/cell versus 39,387 (p = 0.04, Mann-Whitney). MUC1 positive cells, irrespective of treatment group, had a greater proportion of cells in S-phase of the cell cycle 27.9% versus 16.8% (p = 0.0004, Mann-Whitney) and demonstrated more cases of aneuploidy 80.65% versus 42.6% (p < 0.0001). MUC1 levels in primary tumours treated neoadjunctively with 3 weeks of tamoxifen were lower than a comparison group which did not receive tamoxifen. MUC1 should be explored further as an intermediate biomarker for assessment of treatment and prognosis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0167-6806
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
67
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
215-22
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:11561767-Aged,
pubmed-meshheading:11561767-Aneuploidy,
pubmed-meshheading:11561767-Antineoplastic Agents, Hormonal,
pubmed-meshheading:11561767-Breast Neoplasms,
pubmed-meshheading:11561767-Cell Cycle,
pubmed-meshheading:11561767-Female,
pubmed-meshheading:11561767-Flow Cytometry,
pubmed-meshheading:11561767-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:11561767-Humans,
pubmed-meshheading:11561767-Middle Aged,
pubmed-meshheading:11561767-Mucin-1,
pubmed-meshheading:11561767-Neoadjuvant Therapy,
pubmed-meshheading:11561767-Prognosis,
pubmed-meshheading:11561767-Retrospective Studies,
pubmed-meshheading:11561767-Tamoxifen,
pubmed-meshheading:11561767-Tumor Markers, Biological
|
pubmed:year |
2001
|
pubmed:articleTitle |
MUC1 expression in primary breast cancer: the effect of tamoxifen treatment.
|
pubmed:affiliation |
Department of Surgery, University of Newcastle upon Tyne, UK.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|